NEW YORK, Nov. 16 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb today announced that it priced its offer for its 5.75% notes due October 1, 2011. The offer was priced for settlement on Monday, November 27, 2006 as determined in the manner described in the Offer to Purchase dated on November 9, 2006, by reference to the applicable fixed spread (listed below) over the applicable reference United States treasury note, plus an amount equal to any accrued and unpaid interest to but excluding the date of payment of the purchase price. The Reference Treasury was determined at 2:00 p.m., New York Time, November 16, 2006.
Purchase Accrued Price per Interest CUSIP Title Principal Fixed Reference Tender $1,000 per $1,000 of Amount Spreads Treasury Offer Principal Principal Security Outstanding (bps) Yield Yield Amount Amount 11012 5.75% $2,500 20 bps 4.6777% 4.8777% $1,037.16 $8.94 2AG3 Notes due bn October 11, 2011
None of Bristol-Myers Squibb, the dealer manager, the depositary agent, the information agent or the Luxembourg agent makes any recommendation that any holder tender or refrain from tendering all or any portion of the principal amount of their Notes pursuant to the tender offer, and no person or entity has been authorized by any of them to make any such recommendation. Holders must make their own decisions as to whether to tender their Notes, and if so, the principal amount to tender.
This press release is not an offer to purchase or a solicitation of an offer to sell any Notes. The tender offer is being made only pursuant to the terms of the Offer to Purchase dated November 9, 2006. In any jurisdiction where the laws require the tender offer to be made by a licensed broker or dealer, the tender offer will be deemed made on behalf of Bristol-Myers Squibb by Goldman, Sachs & Co., or one or more registered brokers or dealers under the laws of such jurisdiction.
Bristol-Myers Squibb Company is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
Bristol-Myers Squibb
CONTACT: Media, Tony Plohoros, +1-212-546-4379, tony.plohoros@bms.com, orJeff Macdonald, +1-212-546-4824 jeffrey.macdonald@bms.com, or Investors,John Elicker, +1-212-546-3775, john.elicker@bms.com, or Blaine Davis,+1-212-546-4631, blaine.davis@bms.com, all of Bristol-Myers Squibb
Web site: http://www.bms.com/
